ADC Therapeutics SA (ADCT) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ADC Therapeutics SA (ADCT) has outperformed Sionna Therapeutics (SION) over the past year, losing 65.0% versus a loss of 82.8%. Sionna Therapeutics is the larger company by market cap ($221.2 million vs $203.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | SION |
|---|---|---|
| Share price | $1.59 | $4.90 |
| Market cap | $202.99M | $221.24M |
| 1-day change | +11.97% | +1.66% |
| YTD return | -54.96% | -88.09% |
| 1-year return | -64.98% | -82.81% |
| 5-year return | -93.76% | — |
| EPS (TTM) | $-0.60 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $54.97 |
| 52-week low | $0.78 | $4.01 |
| Distance from 52-week high | -68.07% | -91.09% |
| Analyst consensus | none | hold |
| Avg. price target upside | +109.43% | +328.57% |
| Average volume | 1.43M | 2.19M |
| Shares outstanding | 127.67M | 45.15M |
| Employees | 188 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADCT has outperformed SION by 17.8 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
ADCT vs SION FAQ
Which is bigger, ADC Therapeutics SA or Sionna Therapeutics?
Sionna Therapeutics (SION) is larger, with a market capitalization of $221.24M compared with $202.99M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or SION?
ADCT returned -64.98% over the past 12 months, compared with -82.81% for SION (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.